PwCCF’s North American Pharma & Life Sciences Deals Update – Q3 2010

Download

The pharma and life sciences sector continues to shift in response to the increased complexities in global health, demands from public healthcare reform, patent expires, and technological advances, as evidenced by continued high level of M&A activity.

While the total number of deals in Q3 2010 is down 10% to 63 from last quarter, it remained above Q1 2010 activity by almost 20%. Disclosed deal value for the quarter is $30.1 billion versus $25 billion in Q2 2010.